FDA Hepatitis Update - April 27, 2011 FDA Advisory Committee background materials available: boceprevir for Hep C

[Guest guest]

Please do not reply to this message.

Background materials for the April 27, 2011 FDA Antiviral Advisory Committee

meeting to discuss boceprevir, a direct acting antiviral (DAA) intended for the

treatment of hepatitis C, are available on the FDA web site through the

following links...

April 27, 2011: Antiviral Drugs Advisory Committee Meeting Announcement

Draft Agenda for the April 27, 2011 Meeting of the Antiviral Drugs Advisory

Committee (PDF - 42KB)

Draft Questions for the April 27, 2011 Meeting of the Antiviral Drugs Advisory

Committee (PDF - 22KB)

Draft Meeting Roster for the April 27, 2011 Meeting of the Antiviral Drugs

Advisory Committee (PDF - 64KB)

Committee Roster for the April 27, 2011 Meeting of the Antiviral Drugs Advisory

Committee (PDF - 25KB)

Webcast Information for the April 27, 2011 Meeting of the Antiviral Drugs

Advisory Committee (PDF - 16KB)

Briefing Information for the April 27, 2011 Meeting of the Antiviral Drugs

Advisory Committee

Klein

Office of Special Health Issues

Food and Drug Administration

Struble

Division of Antiviral Drug Products

Food and Drug Administration

Other inquiries? webmail@...

U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring,

MD 20993 · 800-439-1420